08

2024

-

08

Hepatology, Army Military Medical University Chai Jin and other teams found that SLC35C1 can reduce cholestatic liver injury and inflammation.

Author:


Inflammation is the key to bile acid (BA)-induced cholestatic liver injury, but the molecular mechanism remains to be elucidated.The solute carrier family 35 member C1 (SLC35C1) transports the guanosine diphosphate group into the Golgi apparatus, facilitating protein glycosylation. Its mutation causes insufficient adhesion of white blood cells and enhances inflammation in humans.However, little is known about its role in liver disease.

On July 10, 2024, Chai Jin, Chen Wensheng, Pan Qiong and Cai Shiying of Yale University jointly communicated inHepatology(IF = 12.9) published online entitled“Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation”of research papers.The study found significant increases in liver SLC35C1 mRNA transcripts and protein expression in patients with obstructive cholestasis and in a mouse model.

Immunofluorescence revealed that up-regulated SLC35C1 expression occurred mainly in hepatocytes.Liver-specific elimination Slc35c1(Slc35c1 cKO) significantly aggravates liver injury in a mouse model of cholestasis induced by bile duct ligation and 1% cholic acid feeding, as manifested by increased hepatic necrosis, inflammation, fibrosis, and bile duct hyperplasia.Slc35c1 cKO increased the expression of hepatic chemokines Ccl2 and Cxcl2, as well as the infiltration of T cells, neutrophils and F4/80 macrophages in the mouse cholestasis model, but did not affect the levels of serum and liver bile acids. Liquid chromatography-tandem mass spectrometry analysis showed that the lack of liver Slc35c1 significantly reduced the fucosylation of cell-cell adhesion protein CEACAM1 at the N153 site.Mechanically, cholestatic levels of conjugated bile acids promote CEACAM1 fucosylation at the N153 site by activating the STAT3 signaling pathway, which stimulates SLC35C1 expression, while CEACAM1 loss of fucosylation at the N153 site enhances BA-stimulated CCL2 and CXCL2 mRNA expression in primary mouse hepatocytes and Primary liver Carcinoma/Poliomyelitis Research Foundation/5-ASBT cells.

Bile acids (BAs) accumulation in the liver can cause cholestatic liver injury.If left untreated, this damage will progress to liver fibrosis, cirrhosis, and liver failure. The authors and others have shown that intrahepatic bile acids can trigger an inflammatory response by stimulating the expression of chemokines such as CCL2 and CXCL2, attracting inflammatory immune cells such as neutrophils and initiating hepatocyte injury. At the same time, bile acids can also activate JAK/STAT3 and P38/MAPK signals (such as RUNX1 and IL32) to trigger a negative feedback loop, inhibit excessive inflammation and reduce cholestatic liver injury. However, it is unclear whether other mechanisms are involved in bile acid-induced liver injury pathology.

The solute carrier family 35 member C(SLC35C) gene, including SLC35C1 and SLC35C2, encodes a nucleotide sugar transport protein that transports guanosine diphosphate-fucose from the cytoplasm into the Golgi apparatus and endoplasmic reticulum (ER) cavity to facilitate protein glycosylation.SLC35C1 and SLC35C2 are expressed in a wide range of organs and tissues, including the liver. Specifically, guanosine diphosphate-fucose is SLC35C1 transported to the Golgi apparatus for protein N-fucosylation, while SLC35C2 is specifically involved in protein O-fucosylation. Mutations in human SLC35C1 cause leukocyte adhesion deficiency type II (LADII) and exacerbate inflammation.SLC35C1 has also been shown to be upregulated in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), but its functional role in liver disease, particularly cholestasis, is unclear.

Pattern mechanism diagram

Carcinoembryonic antigen-related cell adhesion molecule 1(CEACAM1), also known as CD66a and biliary glycoprotein, is a highly glycosylated cell adhesion molecule.It is expressed primarily in epithelial cells (e. g., hepatocytes), endothelial cells, and immune cells. CEACAM1 can modulate cell differentiation, tumorigenesis and metastasis, insulin sensitivity, and mucosal immunity in various diseases, including HCC, nonalcoholic fatty liver disease (NASH), and inflammatory bowel disease. In addition, in a mouse model of autoimmune hepatitis, Ceacam1 deficiency exacerbates liver injury and inflammation by activating innate lymphoid and myeloid lineage cells. In contrast, overexpression of CEACAM1 in liver-specific transgenic mice protected the liver from injury by reducing diet-induced metabolic and inflammatory responses. These observations support the hypothesis of CEACAM1 as a negative regulator of the hepatic inflammatory response. Interestingly, CEACAM1 was detected in the serum and bile of patients with obstructive jaundice and in a rat model of cholestatic liver injury induced by bile duct ligation (BDL). However, little is known about the role of liver CEACAM1 in cholestatic liver injury and its functional association with SLC35C1.

In the present study, the authors investigated the expression and function of liver SLC35C1 in cholestasis.The authors found that liver SLC35C1 expression was significantly upregulated in patients with cholestasis and in a mouse model of cholestasis.Lack of SLC35C1 in the mouse liver significantly exacerbated cholestatic liver injury and inflammation and was associated with reduced fucosylation of CEACAM1 at the N153 site, suggesting that SLC35C1 is a negative regulator of cholestatic liver injury.These findings may contribute to the development of new strategies for the treatment of cholestatic liver diseases.

Chongqing Chongfan Technology Co., Ltd. Optical platform film thickness meter OCT optical coherence tomography LabVIEW control